Enzon Pharmaceuticals Inc., a developer of cancer treatments, said it is considering selling all or part of the business after billionaire investor Carl Icahn expressed interest in talking to the company.
Lazard Ltd. was hired to help explore the possibility of a sale, Piscataway, New Jersey-based Enzon said Monday in a statement. To conserve cash, Enzon suspended development and testing of its androgen receptor treatment.
Icahn said Nov. 28 he had informed the company that he wanted to discuss its operations, direction and plans to manage expenses, according to a regulatory filing. Icahn’s firm owned 13.3 percent of Enzon shares as of Nov. 9. Enzon has a treatment for breast and colorectal cancer in the second of three stages of development typically needed to get regulatory approval.
“Enzon’s drug candidates and technologies offer the potential for a variety of transactions,” Alex Denner, chairman of Enzon’s board, said in the statement.
Enzon shares have fallen 32 percent this year, giving the company a market value of $203 million.
© Copyright 2024 Bloomberg News. All rights reserved.